Skip to content

SAB Biotherapeutics, Inc.

SABS· NasdaqCore metricsCIK 1833214

Biological products, except diagnostic substances175 peers

Close
Oct 29, 2026
Market cap
$294.38M
91.14M shares
Filings
436
$0.00
FY 2025−100.0% FY25 yoy
-$22.30M
Q3 2026N/M FY25 yoy
-$25.90M
Q3 2026N/M FY25 yoy
-$41.05M
Q3 2026derivedN/M FY25 yoy
-$0.24
Q3 2026N/M FY25 yoy
$14.44M
Q3 2026+18.0% FY25 yoy
$294.38M
22.2×
—
1.4×
-15.53%
—

FY2025 figures · derived

Price

$3.23+6.95%+$0.21past year
Oct 29, 2026 · Official close
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$0.00FY 2025
$60.88M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$0reported
FY 20242024-12-31$1,322,410reported
FY 20232023-12-31$2,238,991reported
FY 20222022-12-31$23,904,181reported
FY 20212021-12-31$60,876,078reported
FY 20202020-12-31$55,237,759reported

Segments

Products
Revenue by Products, FY2020 to FY2022FY2020Grant Revenue · FY2020 · $55.24MFY2021Grant · FY2021 · $60.88MGrant Revenue · FY2021 · $60.88MFY2022Grant · FY2022 · $23.90M
LineFY2022ShareChange
Grant$23.90M100%−60.7%
Grant Revenue———
Total$23.90M

From the 10-K filed Apr 14, 2023SABS

Biological products, except diagnostic substances

SAB Biotherapeutics, Inc. is the 79th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR